<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277159</url>
  </required_header>
  <id_info>
    <org_study_id>10105</org_study_id>
    <nct_id>NCT01277159</nct_id>
  </id_info>
  <brief_title>Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine</brief_title>
  <official_title>Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients scheduled to go home after ankle surgery at HSS typically receive a sciatic nerve
      block in the popliteal fossa and oral analgesic tablets (such as Percocet). Popliteal fossa
      nerve blockade has reduced pain for these patients (YaDeau et al, Anesth Analg
      2008;106:1916-20), but unfortunately the patients still often experience moderate to severe
      pain after the block wears off. The investigators wish to study two additives that may
      prolong the period of analgesia provided by the nerve block. The additives will be studied in
      the context of a standardized postoperative multimodal analgesic pathway.

      Primary outcome:

      Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a
      popliteal fossa nerve block?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time it Takes for Nerve Block to Wear Off</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Patients Undergoing Ankle Surgery</condition>
  <arm_group>
    <arm_group_label>Control Nerve Block. IV Dexamethasone (4 mg).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control Nerve Block. IV Dexamethasone (4 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerve Block with Dexamethasone (4 mg). IV saline.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B. Nerve Block with Dexamethasone (4 mg). IV saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A. Control Nerve Block. IV Dexamethasone (4 mg).</intervention_name>
    <description>A. Control Nerve Block. IV Dexamethasone (4 mg).</description>
    <arm_group_label>Control Nerve Block. IV Dexamethasone (4 mg).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B. Nerve Block with Dexamethasone (4 mg). IV saline.</intervention_name>
    <description>B. Nerve Block with Dexamethasone (4 mg). IV saline.</description>
    <arm_group_label>Nerve Block with Dexamethasone (4 mg). IV saline.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</intervention_name>
    <description>C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</description>
    <arm_group_label>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</intervention_name>
    <description>D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</description>
    <arm_group_label>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).</intervention_name>
    <description>E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.</description>
    <arm_group_label>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of Dr Levine or Dr Roberts.

          2. Scheduled for discharge from HSS after foot or ankle surgery.

          3. A single-injection popliteal fossa nerve block is judged appropriate.

          4. Surgery confined to foot and ankle (no iliac crest bone graft planned - iliac aspirate
             is not an exclusion criterion).

          5. Patients aged 18-75 years.

        Exclusion Criteria:

          -  Surgery that will cause pain at sites outside the distal lower extremity (e.g. iliac
             crest bone graft).

          -  Bilateral surgery

          -  Chronic pain (defined as regular use of opioid analgesics for &gt; 3 months).

          -  Chronic use of steroids (defined as regular use of steroids for &gt; 3 months).

          -  Contraindication to performance of the popliteal fossa nerve block with 30 cc 0.25%
             bupivacaine with clonidine (e.g. alleged bupivacaine sensitivity, low body weight,
             clonidine allergy, etc.).

          -  Contraindications to dexamethasone or buprenorphine (e.g. allergy, Insulin Dependent
             Diabetes Mellitus, etc.)

          -  Inability of the patient to describe postoperative pain (e.g. psychiatric disorder,
             dementia).

          -  Non-English speaking patients (the questionnaire is in English, and translations would
             have to be separately validated)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Urban</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <results_first_submitted>March 27, 2017</results_first_submitted>
  <results_first_submitted_qc>August 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2017</results_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Duration</keyword>
  <keyword>Popliteal Fossa Nerve Block</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Additives</keyword>
  <keyword>Ankle surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Nerve Block. IV Dexamethasone (4 mg).</title>
          <description>Control Nerve Block. IV Dexamethasone (4 mg).
A. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).</description>
        </group>
        <group group_id="P2">
          <title>Nerve Block With Dexamethasone (4 mg). IV Saline.</title>
          <description>B. Nerve Block with Dexamethasone (4 mg). IV saline.
B. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.</description>
        </group>
        <group group_id="P3">
          <title>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp</title>
          <description>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</description>
        </group>
        <group group_id="P4">
          <title>Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (</title>
          <description>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</description>
        </group>
        <group group_id="P5">
          <title>Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine</title>
          <description>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
IV saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Nerve Block. IV Dexamethasone (4 mg).</title>
          <description>Control Nerve Block. IV Dexamethasone (4 mg).
A. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).</description>
        </group>
        <group group_id="B2">
          <title>Nerve Block With Dexamethasone (4 mg). IV Saline.</title>
          <description>B. Nerve Block with Dexamethasone (4 mg). IV saline.
B. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.</description>
        </group>
        <group group_id="B3">
          <title>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp</title>
          <description>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</description>
        </group>
        <group group_id="B4">
          <title>Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (</title>
          <description>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</description>
        </group>
        <group group_id="B5">
          <title>Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine</title>
          <description>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
IV saline.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="19"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.29" spread="6.8"/>
                    <measurement group_id="B2" value="47.81" spread="9.5"/>
                    <measurement group_id="B3" value="46.26" spread="7.5"/>
                    <measurement group_id="B4" value="47.95" spread="8.6"/>
                    <measurement group_id="B5" value="52.19" spread="7.2"/>
                    <measurement group_id="B6" value="49.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="19"/>
                    <count group_id="B5" value="16"/>
                    <count group_id="B6" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time it Takes for Nerve Block to Wear Off</title>
        <description>Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?</description>
        <time_frame>up to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Nerve Block. IV Dexamethasone (4 mg).</title>
            <description>Control Nerve Block. IV Dexamethasone (4 mg).
A. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).</description>
          </group>
          <group group_id="O2">
            <title>Nerve Block With Dexamethasone (4 mg). IV Saline.</title>
            <description>B. Nerve Block with Dexamethasone (4 mg). IV saline.
B. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.</description>
          </group>
          <group group_id="O3">
            <title>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp</title>
            <description>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</description>
          </group>
          <group group_id="O4">
            <title>Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (</title>
            <description>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</description>
          </group>
          <group group_id="O5">
            <title>Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine</title>
            <description>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
IV saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Time it Takes for Nerve Block to Wear Off</title>
          <description>Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="5.1"/>
                    <measurement group_id="O2" value="45.1" spread="5.2"/>
                    <measurement group_id="O3" value="32.2" spread="6.1"/>
                    <measurement group_id="O4" value="45.6" spread="5.6"/>
                    <measurement group_id="O5" value="45.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Nerve Block. IV Dexamethasone (4 mg).</title>
          <description>Control Nerve Block. IV Dexamethasone (4 mg).
A. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).</description>
        </group>
        <group group_id="E2">
          <title>Nerve Block With Dexamethasone (4 mg). IV Saline.</title>
          <description>B. Nerve Block with Dexamethasone (4 mg). IV saline.
B. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.</description>
        </group>
        <group group_id="E3">
          <title>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp</title>
          <description>Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)</description>
        </group>
        <group group_id="E4">
          <title>Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (</title>
          <description>Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).</description>
        </group>
        <group group_id="E5">
          <title>Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine</title>
          <description>Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
IV saline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yadeau</name_or_title>
      <organization>HSS</organization>
      <phone>212.606.1206</phone>
      <email>YadeauJ@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

